Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET
Company Participants
Ryan Asay - Vice President of Corporate Affairs
David Meek - Chief Executive Officer
Charles Baum - President, Founder & Head of Research & Development
Laurie Stelzer - Chief Financial Officer
James Christensen - Chief Scientific Officer
Ben Hickey - Chief Commercial Officer
Alan Sandler - Chief Medical Officer
Conference Call Participants
Salveen Richter - Goldman Sachs
Tyler Van Buren - Cowen
Gena Wang - Barclays
Jonathan Miller - Evercore ISI
Michael Schmidt - Guggenheim
Michael Ulz - Morgan Stanley
Jason Gerberry - Bank of America
Maury Raycroft - Jefferies
Eric Joseph - JPMorgan
Benjamin Burnett - Stifel
Andrew Berens - SVB Securities
Yigal Nochomovitz - Citigroup
Silvan Tuerkcan - JMP Securities
Jay Olson - Oppenheimer
Swapnil Malekar - Piper Sandler
Kalpit Patel - B. Riley Securities
Operator
Good afternoon, and welcome to the Mirati Therapeutics Third Quarter 2022 Earnings Call. My name is Jenny, and I will be the operator for today's call. All lines have been placed on mute to prevent any background noise. After the conclusion of the speakers prepared remarks, there will be a question-and-answer session. [Operator Instructions]
It is my pleasure to introduce Ryan Asay, Vice President of Corporate Affairs at Mirati. Ryan, you may begin the call.
Ryan Asay
Thank you, Jenny, and welcome everyone to this afternoon's call. Joining me on the call today are David Meek, our Chief Executive Officer; Dr. Chuck Baum, our President Founder and Head of Research and Development; Dr. Jamie Christensen, our Chief Scientific Officer, Ben Hickey, our Chief Commercial Officer and Laurie Stelzer, our Chief Financial Officer. We are also joined by our recently appointed Chief Medical Officer Dr. Alan Sandler.
Before we begin, I’d like to inform you that certain statements we make during this call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K, and our quarterly reports on Form 10-Q that are filed with the US Securities and Exchange Commission.
This afternoon, we released financial results for the quarter ended September 30, 2022 and recent corporate updates. This press release is available on the Investors section of our website at mirati.com.